NASDAQ · GLUE
Monte Rosa Therapeutics, Inc.
Healthcare · Biotechnology
$11.77▲ 0.43% ($0.05)at close
As of 4:00 PM ET
Market cap
$994.32M
P/E
-5.40
EPS (TTM)
-$1.89
Next earnings
Nov 5, 2026
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 36.3% revenue growth a year for 10 years. Our scenarios assume 10.1–17.4%.
That's below its past 1-year pace of 63.5%.
Value per share
Base case
$7.58
Price used $11.77 is 1.6× this
USD · TTM ending Jun 30, 2026 · Price Sep 25, 8:00 PM UTC
Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
1 more note
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Revenue each value needs
Revenue today $28.7M. The price needs $635M by 2036. Base case: $106M. At its recent pace: $3.9B. Bear to Bull: $74.9M to $143M.
Revenue today $28.7M. The price needs $635M by 2036. Base case: $106M. At its recent pace: $3.9B. Bear to Bull: $74.9M to $143M.
Revenue in 2036
today $28.7M
+$528Mmore than the Base case · 6.0×
Value per share · Base case
$7.58
Price $11.77
1.6× this
- 10-yr revenue CAGR
- 14.0%
- Ending operating margin
- 0.0%
- Discount rate
- 13.1%
Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
1 more note
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
USD · TTM ending Jun 30, 2026 · Price Sep 25, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 79.69% over the last year. Revenue declined 83.86% over the trailing twelve months. Operating margin moved from 8.4% to -633.04%. Free cash flow declined 398.99% over the trailing twelve months.
What the market seems to be pricing
The stock is rising despite deteriorating fundamentals and now sits at the 78th percentile of its historical P/S range. This is a momentum-driven move — the market may be front-running a recovery that has not yet appeared in reported numbers.
What would invalidate this read
Operating margin (currently -633.04%) would need to stabilize or improve to justify the move. Revenue is declining 83.86% — a trend reversal in the next report would be the key signal to watch. This read is wrong if the next period shows operating metrics turning the corner. At that point the price would be anticipating real improvement rather than running ahead of it.
Return analysis
Company profile
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
7
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q4 FY26 · EPS est -$0.23 · Revenue est $31.11M
View
Institutional Sentiment
Monte Rosa Therapeutics, Inc. · GLUE
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.